Bioengineering to combat the tuberculosis pandemic

Project overview

We will combine engineering and biological approaches to investigate the host-pathogen interaction and identify new therapeutic targets.

Staff

Lead researcher

Professor Paul Elkington

Director of Inst. for Medical Innovation

Research interests

tuberculosis
immunopathology
diagnosis

Connect with Paul

Email: p.elkington@soton.ac.uk

Other researchers

Professor Xunli Zhang PhD, DIC, FRSC, CChem, CEng

Head of Department-Chemical Engineerg

Research interests

Xunli’s key expertise lies in the area of microfluidics technology from design and fabrication of microfluidic devices, through the development of in-situ monitoring methods for bio/chemical processes, to microfluidic modelling, microsystems integration and automation. The application is largely associated with biomedical challenges like patient specific design of microfluidic devices for cancer treatment, rapid diagnosis, and tackling antimicrobial resistance (AMR). The continuous flow reactors have been used for the synthesis of a range of nanoparticles, both organic and inorganic, for application in drug delivery and energy saving. The technologies developed in his research have also found great potential for industrial applications through a variety of industrial collaborations.

Connect with Xunli

Email: xl.zhang@soton.ac.uk

Research outputs

A Personal respirator to improve protection for healthcare workers treating COVID-19 (PeRSo)

Paul Elkington,

Alexander Dickinson,

Mark Mavrogordato,

Daniel Spencer,

Richard Gillams,

Antonio De Grazia,

Sebastian Rosini,

Diana Garay Baquero,

Laura Diment,

Nitin Mahobia,

Alexandra Mant,

Tom Baynham,

& Hywel Morgan

, 2021 , Frontiers in Medical Technology: Regenerative Technologies , 3 (664259) , 1--11

DOI: 10.3389/fmedt.2021.664259

Type: article

Doxycycline host-directed therapy in human pulmonary tuberculosis

Quig Miow,

Andres Vallejo Pulido,

Yu Wang,

Jia Hong,

Chen Bai,

Felicia Teo,

Alvin Wang,

Hong Loh,

Tuan Tan,

Ying Ding,

Hoi She,

Suay Gan,

Nicholas Paton,

Josephine Lum,

Alicia Tay,

Cynthia Chee,

Paul Tambyah,

Marta Polak,

Yee Wang,

Amit Singhal,

Paul Elkington,

Jon S. Friedland,

& Catherine W.M. Ong

, 2021 , Journal of Clinical Investigation , 131 (15)

DOI: 10.1172/JCI141895

Type: article

Integrated transcriptomic analysis of human tuberculosis granulomas and a biomimetic model identifies therapeutic targets

Michaela T. Reichmann,

Liku Bekele Tezera,

Andres Vallejo Pulido,

Milica Vukmirovic,

Rui Xiao,

James Reynolds,

Sanjay Jogai,

Susan Wilson,

Benjamin Marshall,

Mark Jones,

Alasdair Leslie,

Jeanine M. D'Armiento,

Naftali Kaminski,

Marta Polak,

& Paul Elkington

, 2021 , Journal of Clinical Investigation , 131 (15) , 1--16

DOI: 10.1172/JCI148136

Type: article

Powered respirators are effective, sustainable, and cost-effective personal protective equipment for SARS-CoV-2

Alasdair Munro,

Jacqui Prieto,

Emmanouil Mentzakis,

Mohammed AM Mansour,

Nitin Mahobia,

Peter Baker,

Sarah Herbert,

Trevor Smith,

Matthew Hine,

Joann Hall,

Angie McClarren,

Mike Davidson,

Julie Brooks,

Jane Fisher,

David Griffiths,

Hywel Morgan,

Corrado Giulietti,

Saul Faust,

& Paul Elkington

, 2021 , Frontiers in Medical Technology: Regenerative Technologies , 3 (October 2021) , 1--13

DOI: 10.3389/fmedt.2021.729658

Type: article

Anti-PD-1 immunotherapy leads to tuberculosis reactivation via dysregulation of TNF-alpha

Liku Bekele Tezera,

Magdalena Bielecka,

Paul Ogongo,

Naomi Walker,

Matthew Ellis,

Diana J. Garay-Baquero,

Kristian Thomas,

MICHAELA REICHMANN,

David Johnston,

Katalin Wilkinson,

Mohamed Ahmed,

Sanjay Jogai,

Suwan N. Jayasinghe,

Robert J. Wilkinson,

Salah Mansour,

Gareth Thomas,

Christian Ottensmeier,

Alasdair Leslie,

& Paul Elkington

, 2020 , eLife , 9

DOI: 10.7554/eLife.52668

Type: article